Stage-specific embryonic antigen 3 (SSEA-3)

Stage-specific embryonic antigen 3 (SSEA-3) is a cell surface glycosphingolipid, specifically a pentasaccharide globoside (Gb5), that serves as a critical marker for pluripotent stem cells and cancer stem cells [8, 13, 25]. It is a member of the Globo-series glycolipids and acts as a precursor for other tumor-associated carbohydrate antigens (TACAs) like SSEA-4 and Globo H [19, 22, 30]. In normal physiology, SSEA-3 expression is tightly regulated during embryonic development and is found on a subpopulation of adult stem cells known as Multilineage-differentiating Stress Enduring (Muse) cells, which possess significant regenerative potential [6, 20, 35]. In oncology, SSEA-3 is aberrantly overexpressed in various malignancies, including breast, colorectal, and oral cancers, where it identifies a highly tumorigenic population of cancer stem cells [1, 3, 7, 17]. Therapeutic strategies targeting SSEA-3 include the development of monoclonal antibodies, CAR-T cells, and vaccines (such as Adagloxad simolenin) that aim to induce apoptosis or immune-mediated clearance of SSEA-3-positive cancer cells [15, 16, 19, 33]. Additionally, SSEA-3 is utilized in regenerative medicine to isolate Muse cells for the treatment of conditions like ischemic stroke and liver cirrhosis [12, 20, 31].

Other names

Gal-Gb4CerGloboside-5Gb5Galactosyl-globosideStage-specific embryonic antigen-3

Targeting of SSEA-3-expressing cells via antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC), and induction of apoptosis through inhibition of the Globo-series biosynthetic pathway (e.g., B3GALT5 inhibition).